clofibrate has been researched along with aluminum in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (90.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Desager, JP; Harvengt, C | 1 |
Kronenwerth, D; Wallerstein, PV | 1 |
Buchmann, P; Göschke, H; Koller, F; Stähelin, HB; Strub, P; Thiel, G | 1 |
Hasegawa, R; Kurokawa, Y; Sai, K; Takagi, A; Umemura, T | 1 |
Locher, JT; Maier, R; Stähelin, HB | 1 |
Hayashi, E; Nagakura, T; Takeshita, R; Tomita, T | 1 |
Hartmann, G; Stähelin, HB | 1 |
Siegel, C | 1 |
Cloarec, M | 1 |
Fitzgerald, O; Heffernan, A; Hickey, N; Mulcahy, R | 1 |
1 trial(s) available for clofibrate and aluminum
Article | Year |
---|---|
[Long-term effect of alufibrate in various types of hyperlipidaemia (author's transl)].
Topics: Adult; Aged; Aluminum; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Drug Evaluation; Drug Tolerance; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Phospholipids; Time Factors; Triglycerides | 1974 |
9 other study(ies) available for clofibrate and aluminum
Article | Year |
---|---|
Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers.
Topics: Adult; Aluminum; Biological Availability; Clofibrate; Female; Humans; Kinetics; Male; Time Factors | 1977 |
[Clinical experiences with vasoatherolip in early cerebral insufficiency].
Topics: Aged; Aluminum; Brain Diseases; Clofibrate; Drug Evaluation; Female; Humans; Male; Middle Aged; Nicotinic Acids; Psychometrics | 1976 |
[Studies on the heredity and pathogenesis of familial combined hyperlipidemia ("multiple lipoprotein type" hyperlipidemia)].
Topics: Adolescent; Adult; Aged; Aluminum; Blood Group Antigens; Cholesterol; Clofibrate; Female; HLA Antigens; Humans; Hyperlipidemias; Male; Middle Aged; Pedigree; Phenotype; Triglycerides | 1976 |
Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators; di(2-ethylhexyl) phthalate, aluminium clofibrate and simfibrate.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aluminum; Animals; Catalase; Clofibrate; Death; Deoxyguanosine; Diethylhexyl Phthalate; DNA; DNA Damage; Hypolipidemic Agents; Kidney; Liver; Male; Microbodies; Oxidation-Reduction; Phthalic Acids; Rats; Time Factors | 1990 |
Effect of Al-chlorophenoxyisobutyrate (Alufibrate) on pyruvate metabolism and on the fate of very low density lipoprotein lipids in hyperlipidemic patients.
Topics: Adult; Aluminum; Butyrates; Carbon Dioxide; Carbon Radioisotopes; Cholesterol; Clofibrate; Electrophoresis; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Phenyl Ethers; Polysaccharides; Pyruvates; Respiration; Time Factors; Triglycerides | 1974 |
Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. I. The effect of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in normal rats.
Topics: Aluminum; Animals; Anticholesteremic Agents; Body Weight; Butyrates; Cholesterol; Clofibrate; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hypolipidemic Agents; Lipid Metabolism; Liver; Liver Glycogen; Male; Organ Size; Phenols; Phospholipids; Rats; Triglycerides | 1973 |
[Antilipemic agents--long term therapy and tolerance].
Topics: Adult; Aged; Aluminum; Clofibrate; Drug Tolerance; Female; Humans; Hypolipidemic Agents; Lipids; Long-Term Care; Male; Middle Aged | 1973 |
[Classification and treatment of hyperlipidemia: normolipemic treatments in 1972].
Topics: Aluminum; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Triglycerides; Xanthomatosis | 1972 |
The chemotherapy of hypercholesterolaemia.
Topics: Aluminum; Androsterone; Anticholesteremic Agents; Clofibrate; Estrogens; Female; Humans; Hypercholesterolemia; Male; Nicotinic Acids; Propionates; Triparanol | 1969 |